000			02162 a2200589 4500
005			20250514052658.0
264		0	_c20021217
008			200212s 0 0 eng d
022			_a1539-3704
024	7		_a10.7326/0003-4819-137-11-200212030-00008 _2doi
040			_aNLM _beng _cNLM
100	1		_aGreenspan, Susan L
245	0	0	_aSignificant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. _h[electronic resource]
260			_bAnnals of internal medicine _cDec 2002
300			_a875-83 p. _bdigital
500			_aPublication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAlendronate _xadverse effects
650	0	4	_aBiomarkers _xanalysis
650	0	4	_aBone Density _xdrug effects
650	0	4	_aDouble-Blind Method
650	0	4	_aDrug Therapy, Combination
650	0	4	_aEstrogen Replacement Therapy _xadverse effects
650	0	4	_aEstrogens, Conjugated (USP) _xadverse effects
650	0	4	_aFemale
650	0	4	_aHip _xphysiology
650	0	4	_aHumans
650	0	4	_aLumbar Vertebrae _xdrug effects
650	0	4	_aMiddle Aged
650	0	4	_aOsteoporosis, Postmenopausal _xdrug therapy
650	0	4	_aPlacebos
650	0	4	_aTreatment Outcome
650	0	4	_aWithholding Treatment
700	1		_aEmkey, Ronald D
700	1		_aBone, Henry G
700	1		_aWeiss, Stuart R
700	1		_aBell, Norman H
700	1		_aDowns, Robert W
700	1		_aMcKeever, Clark
700	1		_aMiller, Sam S
700	1		_aDavidson, Michael
700	1		_aBolognese, Michael A
700	1		_aMulloy, Anthony L
700	1		_aHeyden, Norman
700	1		_aWu, Mei
700	1		_aKaur, Amarjot
700	1		_aLombardi, Antonio
773	0		_tAnnals of internal medicine _gvol. 137 _gno. 11 _gp. 875-83
856	4	0	_uhttps://doi.org/10.7326/0003-4819-137-11-200212030-00008 _zAvailable from publisher's website
999			_c12264835 _d12264835